Combined Treatment with Acalabrutinib and Rapamycin Inhibits Glioma Stem Cells and Promotes Vascular Normalization by Downregulating BTK/mTOR/VEGF Signaling

Glioblastoma (GBM) is the most common primary malignant brain tumor in adults, with a median duration of survival of approximately 14 months after diagnosis. High resistance to chemotherapy remains a major problem. Previously, BTK has been shown to be involved in the intracellular signal transductio...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Yu-Kai, Bamodu, Oluwaseun Adebayo, Su, I-Chang, Pikatan, Narpati Wesa, Fong, Iat-Hang, Lee, Wei-Hwa, Yeh, Chi-Tai, Chiu, Hsiao-Yean, Lin, Chien-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464793/
https://www.ncbi.nlm.nih.gov/pubmed/34577576
http://dx.doi.org/10.3390/ph14090876

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464793/
https://www.ncbi.nlm.nih.gov/pubmed/34577576
http://dx.doi.org/10.3390/ph14090876

Ejemplares similares